Name: New Drugs in Allergy and Asthma (en Inglés)
Price: 72440.00 CLP
Availability: InStock
Author: Hansel, T. T. ; Morley
ISBN: 9783034873260

portada New Drugs in Allergy and Asthma (en Inglés)

Formato

Libro Físico

Autor

Christopher Morley

T. T. Hansel

Editorial

Birkhauser

Idioma

Inglés

N° páginas

310

Encuadernación

Tapa Blanda

Dimensiones

24.4 x 17.0 x 1.7 cm

Peso

0.52 kg.

ISBN13

9783034873260

Categorías

Cuestiones generales de la medicina
Ciencias matemáticas
Alergias, incluidas las alimentarias

New Drugs in Allergy and Asthma (en Inglés)

Christopher Morley (Autor) · T. T. Hansel (Autor) · Birkhauser · Tapa Blanda

Libro Nuevo

$ 72.440

$ 131.710

Ahorras: $ 59.270

45% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Viernes 26 de Julio y el Miércoles 07 de Agosto.

Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.

Reseña del libro "New Drugs in Allergy and Asthma (en Inglés)"

Readers will be aware that asthma is one of the commonest chronic diseases of industrialised societies, with an increase in morbidity and mortality, despite the availability of a range of different drugs. In an effort to improve the treatment of asthmatic patients, international guidelines have recently recognised asthma as an inflammatory disease, and there has been a change in emphasis from bronchodilator drugs towards earlier use of anti-inflammatory treatments. This volume brings together the latest developments in our understanding of the mechanisms of asthma, considers the safety ofbeta-adrenoceptor agonists, and explores latest developments in the use of phosphodiesterase (PDE) inhibitors in asthma therapy. The second international conference on "New Drugs in Allergy and Asthma" was held in Davos on 8-10 July 1992. There were six sessions with specialist chairmen: PDE isoenzymes (c. D. Nicholson), atopy and the environment (8. Villiger), adhesion molecules (R. H. Gundel), cytokines (M. Baggiolini), airway hyperreactivity (S. Makino) and neurotransmitters (J. G. Widdicombe). The success of the meeting was ensured by a high standard of presentation, with extensive reference to recent experimental data. The chairmen were instrumental in fostering stimulating discussion periods, that considerably enlivened the meeting. Particular thanks are due to the Swiss Institute for Asthma and Allergy Research (SIAF) and also to the e1inicians of Davos for their assistance and hospitality. In addition, a number of pharmaceutical companies were kind enough to support this meeting that was devoted to academic aspects of drug discovery. John Morley FRCPath.